|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| C12N 15/63 | (2006.01) | ||
| A61K 39/395 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07K 16/32 | (2006.01) | ||
| A61K 47/68 | (2017.01) |
| (11) | Number of the document | 3480215 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18204950.2 |
| Date of filing the European patent application | 2014-11-18 | |
| (97) | Date of publication of the European application | 2019-05-08 |
| (45) | Date of publication and mention of the grant of the patent | 2021-06-23 |
| (46) | Date of publication of the claims translation | 2021-08-25 |
| (30) | Number | Date | Country code |
| 201310586326 | 2013-11-19 | CN |
| (72) |
FANG, Jianmin , CN
HUANG, Changjiang , CN
JIANG, Jing , CN
YAO, Xuejing , CN
LI, Hongwen , CN
XU, Qiaoyu , CN
LI, Zhuanglin , CN
|
| (73) |
RemeGen Co., Ltd. ,
58 Middle Beijing Road
Yantai Economic &
Technological Development Area, Yantai, Shandong 264006,
CN
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | ANTI-HER2 antikūnas ir jo konjugatas |
| ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF |
| Payment date | Validity (years) | Amount | |
| 2025-10-14 | 12 | 289.00 EUR |
| 2026-11-18 |